Departament of Gastroenterology, CIBEREHD, University of Country Basque, Donostia Hospital, Avda. Sancho El Sabio, 17-2D, 20010 San Sebastián, Spain.
World J Gastroenterol. 2010 Feb 21;16(7):862-7. doi: 10.3748/wjg.v16.i7.862.
To evaluate changes in colorectal cancer (CRC) survival over the last 20 years.
We compared two groups of consecutive CRC patients that were prospectively recruited: Group I included 1990 patients diagnosed between 1980 and 1994. Group II included 871 patients diagnosed in 2001.
The average follow up time was 21 mo (1-229) for Group I and 50 mo (1-73.4) for Group II. Overall median survival was significantly longer in Group II than in Group I (73 mo vs 25 mo, P < 0.001) and the difference was significant for all tumor stages. Post surgical mortality was 8% for Group Iand 2% for Group II (P < 0.001). Only 17% of GroupI patients received chemotherapy compared with 50% of Group II patients (P < 0.001).
Survival in colorectal cancer patients has doubled over the past 20 years. This increase seems to be partly due to the generalization in the administration of chemotherapy and to the decrease of post surgical mortality.
评估过去 20 年来结直肠癌（CRC）生存情况的变化。
我们比较了两组连续的 CRC 患者，这些患者是前瞻性招募的：第 I 组包括 1990 名 1980 年至 1994 年期间诊断为 CRC 的患者。第 II 组包括 871 名 2001 年诊断为 CRC 的患者。
第 I 组的平均随访时间为 21 个月（1-229），第 II 组为 50 个月（1-73.4）。第 II 组的总体中位生存时间明显长于第 I 组（73 个月比 25 个月，P <0.001），所有肿瘤分期的差异均有统计学意义。第 I 组术后死亡率为 8%，第 II 组为 2%（P <0.001）。第 I 组仅有 17%的患者接受化疗，而第 II 组有 50%的患者接受化疗（P <0.001）。
在过去的 20 年中，结直肠癌患者的生存率提高了一倍。这种增加似乎部分归因于化疗的广泛应用和术后死亡率的降低。
